[Clinical effectiveness of Marvelon].

In: Ginekologia polska · 1995 · vol. 66(5) , pp. 294–6 · PMID:8522228 · W127674063
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-07, 2026-07-09

Marvelon, a new contraceptive pill, was well-tolerated with low side effects, regular cycles, unchanged bleeding, no impact on weight or blood pressure, and a favorable lipid profile in 32 women over 6 cycles, achieving a Pearl Index of 0.0.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Clinical results of a new contraceptive pills--Marvelon (Organon) were studied. 32 women, ages 30 +/- 5 years, participated in the study during at least 6 cycles. Marvelon was good tolerated and subjective side-effects were very low. The cycles were regular, duration of withdrawal bleeding was 3-5 days and the amount of the blood lost were unchanged or milder. Marvelon didn't affect body weight and blood pressure. Favourable lipid profile--increased a mean level of HDL-Cholesterol and decreased a mean level of LDL-Cholesterol were noticed. Pearl Index was 0,0.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK